Monopar Therapeutics (NASDAQ:MNPR) Stock Price Up 10.3% – Here’s What Happened

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares were up 10.3% on Tuesday . The stock traded as high as $75.80 and last traded at $75.75. 57,507 shares were traded during mid-day trading, a decline of 72% from the average session volume of 206,877 shares. The stock had previously closed at $68.66.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BTIG Research reissued a “buy” rating and issued a $104.00 price target on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a report on Monday, March 30th. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, June 14th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics has an average rating of “Buy” and an average price target of $107.91.

Monopar Therapeutics Trading Up 15.4%

The firm’s fifty day moving average price is $59.89 and its 200-day moving average price is $61.79. The company has a market cap of $530.94 million, a P/E ratio of -41.71 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.41. As a group, research analysts forecast that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE raised its position in Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Monopar Therapeutics in the 1st quarter valued at approximately $250,000. Siren L.L.C. grew its stake in shares of Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after purchasing an additional 57,820 shares during the period. Finally, Sei Investments Co. raised its holdings in shares of Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after buying an additional 656 shares in the last quarter. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.